Business Wire

HeartFlow Announces Decision by Centers for Medicare & Medicaid Services to Assign a New Technology Payment Classification to HeartFlow® FFRct Analysis

Jaa

HeartFlow, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow® FFRct Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD). Under the APC payment system, hospitals enrolled in Medicare that bill CMS for the HeartFlow FFRct Analysis for Medicare patients will be eligible for reimbursement at a rate of $1,450.50 for the technical component of the test. This payment rate will take effect on January 1, 2018.

"The CMS decision to assign a New Technology APC for the HeartFlow FFRct Analysis is a major milestone and will ensure that our innovative, non-invasive technology can be utilized for Medicare beneficiaries. This is a significant development, given the high prevalence of CAD in people over age 65,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “This decision is a testament to the wealth of clinical evidence and cost data that support the use of the HeartFlow FFRct Analysis as a critical, potentially life-saving technology.”

CAD, which today affects 16.8 million Americans,1 develops when the coronary arteries narrow, reducing blood flow to the heart and causing angina (chest pain), myocardial infarction (heart attack) and death. Older individuals are at highest risk of CAD.2 The HeartFlow FFRct Analysis provides insight into both the extent of CAD and the impact of the disease on blood flow to the heart. It uses high-quality images from a coronary computed tomography (CT) angiogram to provide clinicians with functional information in order to offer actionable information on the optimal course of treatment.

According to CMS, more than 55 million Americans are enrolled in the Medicare program.3

“CMS’s decision to assign a New Technology APC for FFRct technology for Medicare recipients is a recognition of the value of this technology and its demonstrated ability to reduce the number of invasive diagnostic coronary angiography procedures and help medical centers reduce costs,” said Pamela Douglas, M.D., Ursula Geller Professor for Research in Cardiovascular Disease in the School of Medicine at Duke University and past president of the American College of Cardiology. “The HeartFlow Analysis is an important tool in helping us assess patients with suspected coronary artery disease and better understand how their coronary blockages affect blood flow to the heart.”

“The decision by CMS will help in the diagnosis and treatment of patients with suspected CAD and means the number of patients over age 65 who will have access to this technology will significantly increase,” said Daniel Simon, M.D., president, University Hospitals (UH) Cleveland Medical Center, and professor of medicine at Case Western Reserve University School of Medicine. “At our center, the use of the HeartFlow FFRct Analysis is transforming how we diagnose and treat patients with coronary artery disease, helping us move closer to achieving the triple aim of improving the patient experience, improving the health of our patients, and reducing healthcare costs at our institution.”

Previously, the American Medical Association (AMA) issued a set of Category III Current Procedural Terminology (CPT®) codes for the HeartFlow FFRct Analysis. These codes provide evidence that the Analysis is a unique and distinct procedure that provides important and actionable clinical information above and beyond that of a coronary CT angiogram. Beginning on January 1, 2018, hospitals utilizing the HeartFlow FFRct Analysis will be able to generate claims when it is ordered for patients with suspected CAD via the use of specific CPT codes.

The CMS decision follows a growing number of commercial payers and professional organizations that have recognized its value in diagnosing patients with suspected CAD. Anthem, Aetna and other Blue Cross Blue Shield companies that collectively provide health insurance for approximately 80 million people have issued positive medical coverage decisions. Evidence Street, which conducts healthcare technology evaluations for the Blue Cross Blue Shield Association, a national federation of 36 independent Blue Cross and Blue Shield companies, issued a positive review. In the U.K., the National Institute for Health and Care Excellence (NICE) of the National Health Service, which covers 64.6 million lives, also issued positive guidance. The American College of Cardiology (ACC) and American Heart Association (AHA) released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease. These criteria include the use of HeartFlow FFRct Analysis in determining the appropriateness of revascularization in many clinical scenarios.

About the HeartFlow FFRct Analysis

With HeartFlow’s technology, data from a patient’s non-invasive coronary CT angiogram are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D model of the patient’s coronary arteries. It then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided to the patient’s physician via a secure web interface.

Clinicians around the world have chosen the HeartFlow FFRct Analysis for more than 15,000 patients to aid in the diagnosis of CAD. HeartFlow’s technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, and significantly reduce healthcare costs for hospitals.4

About HeartFlow, Inc.

HeartFlow, Inc. is transforming the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow® FFRct Analysis is the first available non-invasive solution that enables a physician to more appropriately evaluate whether an individual has significant coronary artery disease (CAD) based on both anatomy and physiology. The HeartFlow FFRct Analysis, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve both clinical outcomes and the patient experience while reducing the cost of care. The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787400/.

2 https://www.nhlbi.nih.gov/health/health-topics/topics/cad/atrisk.

3 https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2015-Press-releases-items/2015-07-28.html.

4 Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.

Contact information

HeartFlow, Inc.
Chris B. Ernst, 415-710-9445
cernst@heartflow.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Norsk Titanium Announces Strategic Investment from Rose Park Advisors’ Disruptive Innovation Fund20.11.2017 16:00Tiedote

Norsk Titanium, the metal additive manufacturing pioneer, today announced it has closed on a significant investment from Rose Park Advisors’ Disruptive Innovation Fund, known for its application of the theory of Disruptive Innovation® developed by co-founder Clayton Christensen. Terms of the investment were not released. “This strategic investment from Rose Park Advisors underscores the ability of Norsk Titanium’s Rapid Plasma Deposition™ (RPD™) technology to disrupt the metal manufacturing processes,” said Norsk Titanium Chairman of the Board John Andersen, Jr. “There are few people that are as widely respected by more business leaders than Dr. Christensen. We are humbled by his recognition of our technology and business model.” “Our strong relationships in commercial aerospace have allowed us to improve our processes and create a platform technology under the watchful eyes

Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com To Unlock Their Full Potential20.11.2017 16:00Tiedote

Boehringer Ingelheim today announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients. “Working together with scientists across the world, we can accelerate research in a wide range of biomedical research areas,“ said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This exciting new initiative further expands Boehringer Ingelheim’s global external innovation footprint and will help unlock the full potential of some of our most interesting compounds. By sharing these compoun

LivaNova Enters into Binding Letter of Intent to Sell its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation for $190 Million20.11.2017 11:43Tiedote

LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort for $190 million in cash. The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures. CRM products include high-voltage defibrillators, cardiac resynchronization therapy devices and low-voltage pacemakers. The CRM Business Franchise generated approximately $249 million in net sales in fiscal year 2016 and has approximately 900 employees with operations chiefly in Clamart, France; Saluggia, Italy; and Santo Domingo, Dominican Republic. MicroPort is a leading medical device company, focused on innova

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study20.11.2017 11:29Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with em

Synteract Thought Leaders to Speak & Exhibit at Partnerships in Clinical Trials Europe in Amsterdam20.11.2017 11:00Tiedote

(Booth #17) – Thought leaders from Synteract, a full-service, international contract research organization (CRO), will exhibit and present at Partnerships in Clinical Trials Europe (PCT), November 28-29, Amsterdam, Netherlands. With awareness of the shifting CRO landscape and the complexity this represents to biopharma companies as they make critical outsourcing decisions, Synteract invites attendees to “Pause to rethink what matters most from your CRO.” Vice President, Global Medical and Regulatory Affairs at Synteract, Dr. Martine Dehlinger-Kremer, will speak on “The EU Clinical Trials Regulation: Are you prepared for its implementation?” at the event on Tuesday, November 28 at noon. She will address how evolving industry needs are driving momentum towards implementation of a new regulation governing clinical trials, the expected impact on sponsors and necessary steps toward p

Fiorano Launches PSD2 Solution for Banks for Seamless Regulatory Compliance20.11.2017 11:00Tiedote

Fiorano Software, a proven global leader in Integration Middleware and API Management, today announced the launch of Fiorano PSD2, a platform solution enabling banks to comply with the European Union’s Revised Payment Service Directive (PSD2) regulations. Fiorano’s end-to-end PSD2 solution is built on the industry's leading banking Integration and API Management infrastructure serving as an onramp for future eDigital Banking initiatives. Banks across Europe need to be PSD2 compliant by January 2018. They are also facing severe competition from FinTechs to improve online payments, customer engagement experiences and making cross-border payments safer. “By building on PSD2 as a solution on top of a tightly integrated API Management and ESB platform, Fiorano masks complex technical details, dramatically simplifies the time and effort for compliance,” said Mr. Atul Saini, CEO of Fio

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme